Literature DB >> 7074214

Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1 + 2 fragment and thrombin--antithrombin complex.

J M Teitel, K A Bauer, H K Lau, R D Rosenberg.   

Abstract

We have evaluated the efficacy of utilizing radioimmunoassays (RIAs) for prothrombin activation fragments (F2/F1 + 2) and for thrombin--antithrombin complex (TAT) in purified systems and in whole blood. During venipuncture, appropriate anticoagulants were employed in order to prevent the generation of thrombin and factor Xa. The RIAs were shown to be specific for F2/F1 + 2 as well as TAT and did not interact with other plasma components. Initially, thrombin generation was studied in a purified human system of prothrombin, antithrombin, factor Xa, and factor V as well as phospholipid and Ca++. Under these conditions, the kinetics of F2/F1 + 2 and TAT generation were virtually superimposable. However, when factor V was omitted from the reaction mixture, a significantly greater amount of F2/F1 + 2 as compared to TAT was observable. Subsequently, prothrombin activation was monitored during the spontaneous coagulation of freshly drawn blood. Throughout the entire course of thrombin generation, the observable rate of formation of F2/F1 + 2 was considerably greater than that of TAT. We have examined the levels of F2/F1 + 2 and TAT in normal individuals. Our studies indicate that the concentrations of F1 + 2 and TAT average 1.97 nM and 2.32 nM, respectively. We have also quantitated the concentrations of F2/F1 + 2 and TAT in patients with disseminated intravascular coagulation. In these individuals, the levels of both components are elevated. However, the ratio of F1 + 2 to TAT ranges from 2.37 to 5.55. Thus, we conclude that under in vivo conditions, prothrombin activation is characterized by the accumulation of a stable precursor, such as prethrombin-2, and that this phenomenon may be related to an alteration of factor V function.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7074214

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  34 in total

1.  Clotting for the Clinician: An Overview of Thrombosis and Antithrombotic Therapy.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

2.  Laboratory Measurement of Thrombin Activity--What Every Clinician Scientist Needs to Know.

Authors: 
Journal:  J Thromb Thrombolysis       Date:  1995       Impact factor: 2.300

3.  Coagulation pathways and diabetic retinopathy: abnormal modulation in a selected group of insulin dependent diabetic patients.

Authors:  C Giusti; R Schiaffini; C Brufani; A Pantaleo; E M Vingolo; P Gargiulo
Journal:  Br J Ophthalmol       Date:  2000-06       Impact factor: 4.638

4.  Activation of blood coagulation in chronic urticaria: pathophysiological and clinical implications. [corrected]

Authors:  Marco Cicardi
Journal:  Intern Emerg Med       Date:  2010-03-27       Impact factor: 3.397

5.  Physiological inhibitors of blood coagulation and prothrombin fragment F 1 + 2 in type 2 diabetic patients with normoalbuminuria and incipient nephropathy.

Authors:  A Mormile; M Veglio; G Gruden; M Girotto; P Rossetto; P D'Este; P Cavallo-Perin
Journal:  Acta Diabetol       Date:  1996-09       Impact factor: 4.280

6.  Aging-associated changes in indices of thrombin generation and protein C activation in humans. Normative Aging Study.

Authors:  K A Bauer; L M Weiss; D Sparrow; P S Vokonas; R D Rosenberg
Journal:  J Clin Invest       Date:  1987-12       Impact factor: 14.808

7.  The Type and Amount of Dietary Fat Affect Plasma Factor VIIc, Fibrinogen, and PAI-1 in Healthy Individuals and Individuals at High Cardiovascular Disease Risk: 2 Randomized Controlled Trials.

Authors:  Penny M Kris-Etherton; Paul W Stewart; Henry N Ginsberg; Russell P Tracy; Michael Lefevre; Patricia J Elmer; Lars Berglund; Abby G Ershow; Thomas A Pearson; Rajasekhar Ramakrishnan; Stephen F Holleran; Barbara H Dennis; Catherine M Champagne; Wahida Karmally
Journal:  J Nutr       Date:  2020-08-01       Impact factor: 4.798

8.  Nonvalvular atrial fibrillation: evidence for a prothrombotic state.

Authors:  S R Kahn; S Solymoss; K M Flegel
Journal:  CMAJ       Date:  1997-09-15       Impact factor: 8.262

9.  Changes in amniotic fluid concentration of thrombin-antithrombin III complexes in patients with preterm labor: evidence of an increased thrombin generation.

Authors:  Offer Erez; Roberto Romer; Edi Vaisbuch; Tinnakorn Chaiworapongsa; Juan Pedro Kusanovic; Shali Mazaki-Tovi; Francesca Gotsch; Ricardo Gomez; Eli Maymon; Percy Pacora; Samuel S Edwin; Chong Jai Kim; Nandor Gabor Than; Pooja Mittal; Lami Yeo; Zhong Dong; Bo Hyun Yoon; Sonia S Hassan; Moshe Mazor
Journal:  J Matern Fetal Neonatal Med       Date:  2009-11

10.  Haemostatic activity in patients with atrial fibrillation treated with low-molecular-weight heparin before and after electrical cardioversion.

Authors:  Elisabeth L Zeuthen; Jens Flensted Lassen; Steen E Husted
Journal:  J Thromb Thrombolysis       Date:  2004-06       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.